Ani Pharmaceuticals (ANIP) Revenue (2010 - 2026)

Ani Pharmaceuticals has disclosed Revenue across 17 years of filings, most recently posting $237.5 million for Q1 2026.

• Revenue for Q1 2026 came in at $237.5 million, up 20.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $923.7 million (up 37.03% YoY), and the FY2025 annual result was $883.4 million, up 43.78% from the prior year.
• Revenue came in at $237.5 million for Q1 2026 at Ani Pharmaceuticals, down from $247.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $247.1 million in Q4 2025 to a low of $64.5 million in Q1 2022.
• The 5-year median for Revenue is $137.4 million (2024), against an average of $149.3 million.
• Across the five-year window, Revenue soared 475.69% in 2022 and gained 12.52% in 2024, its largest moves.
• Ani Pharmaceuticals' Revenue stood at $94.2 million in 2022, then surged by 39.71% to $131.7 million in 2023, then soared by 44.75% to $190.6 million in 2024, then rose by 29.64% to $247.1 million in 2025, then retreated by 3.88% to $237.5 million in 2026.
• The last three Revenue figures came in at $237.5 million (Q1 2026), $247.1 million (Q4 2025), and $227.8 million (Q3 2025), per Business Quant data.